Publications

Broome C, Hausrath D, Jaworski J, Fernandez S, Edwards T,…, Bylsma L, Kelsh M,.., Mitchell M. Survival outcomes of patients with secondary hemophagocytic lymphohistiocytosis at two academic medical centers in the United States. Poster 905, Blood 146(Sup 1):6243; doi: 10.1182/blood-2025-6243. 67^th American Society of Hematology (ASH) Annual Meeting and Exposition, Orlando, FL, November 2025.

Johnson W, Covert K, Mitchell M, Kelsh M, Mangal B, Bose M, Dong K, Dao K-H. Real-world outcomes with available therapies in secondary hemophagocytic lymphohistiocytosis (sHLH): A natural history study with an embedded historical control arm. Poster 19, Histiocyte Society 41^st Annual Meeting, Seattle, WA, September 2025.

Shaw J, Hsu H, Tu H, Chia V, Aggarwal S, Carrigan G, Kelsh MA. Immortal time bias impacts time-to-time event outcomes in cohort with genomic testing. Abstract 6F-03, International Society for Pharmacoepidemiology (ISPE) 41^st Annual Meeting, Washington, DC, August 2025.

Kelsh M, Bylsma LC, Jiang X, Movva N, Sacks NC. To be an orphan disease or not to be: An evaluation of prevalence estimates for cancers near the orphan status threshold and implications for orphan drug planning. International Society for Pharmacoepidemiology, 40^th Annual Meeting, Berlin, Germany, August 2024.

Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S. 2022. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 30(7):6327–6338; doi: 10.1007/s00520-022-06967-x. PMID: 35482126.

Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M, et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer. Adv Ther 39(6):2778–2795; doi:10.1007/s12325-022-02141-1. PMID: 35430673.

McGrath LJ, Nielson C, Saul B, Breskin A, Yu Y, Nicolaisen SK, … Kelsh M, et al. 2021. Lessons learned using real-world data to emulate randomized trials: A case study of treatment effectiveness for newly diagnosed immune thrombocytopenia. Clin Pharmacol Ther 110(6):1570–1578; doi: 10.1002/cpt.2399. PMID: 34416023.

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315; doi: 10.1016/j.jgo.2020.06.018. PMID: 32624415.

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882; doi: 10.1016/j.clml.2020.06.007. PMID: 32792304.

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. 2020. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. Curr Med Res Opin 36(9):1519–1527; doi: 10.1080/03007995.2020.1801403. PMID: 32715807.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. 2020. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 28(9):4413–4424; doi: 10.1007/s00520-020-05295-2. PMID: 31919669.

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478; doi: 10.1038/s41375-020-0770-8. PMID: 32094465.

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057; doi: 10.1002/cam4.2747. PMID: 31856410.

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186; doi: 10.1007/s13187-019-01638-8. PMID: 31656028.

Danese MD, Katz A, Cetin K, Chia V, Gleeson ML, Kelsh M, et al. 2019. Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: An observational cohort study using SEER Medicare data. Leuk Lymphoma 60(8):2015–2024; doi: 10.1080/10428194.2018.1555329. PMID: 30632830.

Bylsma LC, Gillezeau C, Garawin T, Kelsh M, Fryzek J, Sangare L, Lowe KA. Prevalence of RAS and BRAF mutations in Metastatic Colorectal Cancer (mCRC) patients by tumor location. Presented at the Gastrointestinal Cancers Symposium, San Francisco, CA, January 2018.

Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, Hessel PA,.., Kelsh MA, et al. 2016. Response to Kay Teschke. Re: Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(8):1036-1037; doi: 10.1093/annhyg/mew038. PMID: 27328807.

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473; doi: 10.1038/bcj.2016.84. PMID: 27662202.

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA. 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181; doi: 10.1007/s12029-016-9809-5.